In announcement no. 15-09 of 7 May 2009, NeuroSearch announced the launch of a
share purchase programme under which the company will buy own shares for an
amount of up to DKK 50 million during 2009.

The programme is structured according to European Commission Regulation No
2273/2003 of 22 December 2003, also referred to as the “Safe Harbour” rules,
for the purchase of own shares.

In the past week, since the issue of status announcement no. 37-09 of 24 August
2009, the following transactions have been made under NeuroSearch's share
purchase programme:

Accumulated share purchase / Number of shares / Average price (DKK)/
Transaction value (DKK)

24 August 2009 3,000 124.00 372,000
25 August 2009 7,500 122.60 919,500
26 August 2009 10,000 121,88 1,218,800
27 August 2009 4,579 122.94 562,928
28 August 2009 4,000 126.83 507,320
Total 29,079 123.13 3,580,548


With the purchased amount of shares as stated above, NeuroSearch now holds a
total of 243,287 treasury shares of DKK 20 nominal value each, corresponding to
1.41% of the total number of 17,237,830 issued shares in NeuroSearch A/S.

An amount of DKK 23,159,877 remains to be used under the share purchase
programme. Based on the closing price for NeuroSearch shares on NASDAQ OMX
Copenhagen on Friday 28 August 2009, this corresponds to a maximum of 182,361
additional NeuroSearch shares to be bought under the programme.


Flemming Pedersen
CEO


Contact persons:

Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103



About NeuroSearch
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and license collaboration with Abbott. The drug pipeline
comprises seven clinical (Phase I-III) development programmes:
Huntexil™(Pridopidine) for Huntington's disease (Phase III), tesofensine for
obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with
Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias
in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase
I) and NSD-721 for social anxiety disorder (Phase I). In addition, NeuroSearch
has a broad portfolio of preclinical drug candidates and holds equity interests
in several biotech companies.

fonds.41-09 - share purchase programme - 16th update - uk - final.pdf